BETHESDA, Maryland, Jan. 23 (TNSjou) -- The National Institutes of Health's National Heart, Lung and Blood Institute issued the following news release: * * * JOURNAL: New England Journal of Medicine * * * Findings from a randomized, non-blinded, phase 3 clinical trial supported by the National Institutes of Health found no significant difference in 90-day mortality rates, nor safety concerns, after providing patients with one of two common treatment strategies for sepsis. The findings were  more